JZL 184
Based on 9 publication(s) in Google Scholar
JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.46%
- No. CAS: 1101854-58-3
- Fòrmula: C27H24N2O9
- Peso molecular:520.49
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-15859
AtglistatinATGL Inhibitor -
HY-18977
KML29MAGL Inhibitor -
HY-117632
ElcubragistatMAGL Inhibitor -
HY-117474
MJN110MAGL Inhibitor -
HY-108613
JJKK 048MAGL Inhibitor -
HY-10864
URB-597FAAH Inhibitor -
HY-Y0873
PEG300Neutral Polymer -
HY-100337
WWL70ABHD6 Inhibitor -
HY-12332
JW 642MAGL Inhibitor -
HY-15371
ForskolinAdenylate Cyclase Activator -
HY-50856
RuxolitinibJAK1/2 Inhibitor -
HY-120177
KT182
Publications Citing Use of MedChemExpress (MCE) JZL 184
More- Research (Wash D C). 2025 Dec 9:8:1031. [Abstract]
- Int J Biol Sci. 2022 Oct 18;18(16):6114-6128. [Abstract]
- Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]
- Free Radic Biol Med. 2025 Nov 14:243:67-81. [Abstract]
- Cells. 2019 Apr 29;8(5):395. [Abstract]
- Cancer Metab. 2025 Feb 11;13(1):8. [Abstract]
- Inflammation. 2026 Mar 3;49(1):92. [Abstract]
- bioRxiv. 2026 Mar 16.
- Research Square Preprint. 2024 Oct 18.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Cell Imaging/Staining
-
Flow Cytometry
-
WB
Actividad biológica
Descripciòn
IC50 & Target
IC50: 8 nM (2-Arachidonoylglycerol (2-AG) hydrolysis)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| COS-7 | IC50 |
0.002 μM
Compound: 3, JZL184
|
Inhibition of human MAGL expressed in monkey COS7 cells
Inhibition of human MAGL expressed in monkey COS7 cells
|
[PMID: 23455058] |
| COS-7 | IC50 |
0.008 μM
Compound: 3, JZL184
|
Inhibition of recombinant MAGL (unknown origin) expressed in monkey COS7 cells
Inhibition of recombinant MAGL (unknown origin) expressed in monkey COS7 cells
|
[PMID: 23455058] |
| COS-7 | IC50 |
0.025 μM
Compound: 3, JZL184
|
Inhibition of rat MAGL expressed in monkey COS7 cells
Inhibition of rat MAGL expressed in monkey COS7 cells
|
[PMID: 23455058] |
| COS-7 | IC50 |
2 nM
Compound: JZL184
|
Inhibition of human MAGL expressed in COS7 cells using endogenous 2-AG substrate
Inhibition of human MAGL expressed in COS7 cells using endogenous 2-AG substrate
|
[PMID: 22738638] |
| COS-7 | IC50 |
4 nM
Compound: 6, JZL184
|
Inhibition of recombinant FAAH expressed in Cos7 cells after 30 mins by using anandamide as a substrate by LC-MS method
Inhibition of recombinant FAAH expressed in Cos7 cells after 30 mins by using anandamide as a substrate by LC-MS method
|
[PMID: 19029917] |
| COS-7 | IC50 |
6 nM
Compound: 6, JZL184
|
Inhibition of recombinant MAGL expressed in Cos7 cells after 30 mins by using 2-AG as a substrate by LC-MS method
Inhibition of recombinant MAGL expressed in Cos7 cells after 30 mins by using 2-AG as a substrate by LC-MS method
|
[PMID: 19029917] |
| COS-7 | IC50 |
8 nM
Compound: 3, JZL184
|
Inhibition of mouse recombinant MAGL expressed in african green monkey COS7 cells assessed as inhibition of 2-AG hydrolysis after 30 mins by LC-MS analysis
Inhibition of mouse recombinant MAGL expressed in african green monkey COS7 cells assessed as inhibition of 2-AG hydrolysis after 30 mins by LC-MS analysis
|
[PMID: 21982493] |
In Vitro
JZL 184 displays IC50 values of 8 nM and 4 μM for blockade of 2-AG and oleamide (FAAH substrate) hydrolysis in brain membranes, respectively. Comparable inhibitory effects are observed with recombinant MAGL and FAAH when expressed in COS7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
JZL 184 prolongs depolarization-induced suppression of excitation (DSE) in Purkinje neurons in cerebellar slices and DSE inhibition (DSI) in CA1 pyramidal neurons in hippocampal slices. JZL 184 produces greater enhancement of DSE/DSI in mouse neurons than that in rat neurons[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57Bl/6 mice (6-8 weeks old, 20-26 g)[1]
-
Dosage:4 mg/kg, 8 mg/kg, 16 mg/kg, 40 mg/kg
-
Administration:Intraperitoneal injection; once
-
Result:Produced a rapid and sustained blockade of brain 2-AG hydrolase activity in mice, resulting in 8-fold elevations in endogenous 2-AG levels that were maintained for at least 8 h.
Chemical Information
-
No. CAS 1101854-58-3
-
Appearance Solid
-
Peso molecular 520.49
-
Fòrmula C27H24N2O9
-
Color White to off-white
-
SMILES
OC(C1=CC=C(OCO2)C2=C1)(C3CCN(C(OC4=CC=C([N+]([O-])=O)C=C4)=O)CC3)C5=CC(OCO6)=C6C=C5
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Research (Wash D C)
Endocannabinoids Block Headache and Anxiety Comorbidity via Two-Pronged Anterior Insular Projections. [Abstract]2025 Dec 9:8:1031. PMID: 41377021
JZL 184 purchased from MedChemExpress. Usage Cited in: Research (Wash D C). 2025 Dec 9:8:1031. [Abstract]
JZL 184 (10 mg/kg; i.p.; 2 h) markedly improved both cephalic cutaneous allodynia and anxiety-like behaviors of ISDN-injected mice.
-
Int J Biol Sci
Stearoyl-CoA Desaturase-1 dependent lipid droplets accumulation in cancer-associated fibroblasts facilitates the progression of lung cancer. [Abstract]2022 Oct 18;18(16):6114-6128. PMID: 36439884
JZL 184 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2022 Oct 18;18(16):6114-6128. [Abstract]
JZL 184 (iMAGL) (20 nM; 12 h) significantly downregulated the number of LDs in fibroblasts (NIH 3T3 and MEF).
JZL 184 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2022 Oct 18;18(16):6114-6128. [Abstract]
The BODIPY staining (FITC) of fibroblasts (NIH 3T3 and MEF) that were treated with/without sodium oleate (50 µM) and JZL 184 (iMAGL) (20 nM; 12 h).
JZL 184 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2022 Oct 18;18(16):6114-6128. [Abstract]
The protein expression of α-SMA and COL1A2 in fibroblasts (NIH 3T3 and MEF) that were treated with/without sodium oleate (50 µM) and JZL 184 (iMAGL) (20 nM; 24 h).
-
Oncogene
Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-κB activation and promotes docetaxel efficacy in prostate cancer. [Abstract]2024 Sep;43(38):2835-2849. PMID: 39155296 -
Free Radic Biol Med
Inhibition of MAGL ameliorates glucocorticoid-induced bone loss by regulating the Nrf2 signaling. [Abstract]2025 Nov 14:243:67-81. PMID: 41242471
JZL 184 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Nov 14:243:67-81. [Abstract]
JZL 184 (16 mg/kg; i.p.; once daily for 16 d) ameliorated GC-induced bone loss in C57BL/6J mice.
-
Cells
An Epistatic Interaction between Pnpla2 and Lipe Reveals New Pathways of Adipose Tissue Lipolysis. [Abstract]2019 Apr 29;8(5):395. PMID: 31035700 -
Cancer Metab
Carboxylesterase 1-mediated endocannabinoid metabolism in skin: role in melanoma progression in BRafV600E/Pten-/- mice. [Abstract]2025 Feb 11;13(1):8. PMID: 39934865 -
Inflammation
MAGL Inhibition Relieves Psoriasiform Inflammation and Pruritus Via Modulation of ALOX12-12-HETE Axis in Mice. [Abstract]2026 Mar 3;49(1):92. PMID: 41774275 -
-
Solvente y solubilidad
In Vitro:
DMSO : ≥ 35 mg/mL (67.24 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.80 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (283 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Long JZ, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009 Jan;5(1):37-44. [Content Brief]
[2]. Pan B, et al. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther. 2009 Nov;331(2):591-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9213 mL | 9.6063 mL | 19.2127 mL | 48.0317 mL |
| 5 mM | 0.3843 mL | 1.9213 mL | 3.8425 mL | 9.6063 mL | |
| 10 mM | 0.1921 mL | 0.9606 mL | 1.9213 mL | 4.8032 mL | |
| 15 mM | 0.1281 mL | 0.6404 mL | 1.2808 mL | 3.2021 mL | |
| 20 mM | 0.0961 mL | 0.4803 mL | 0.9606 mL | 2.4016 mL | |
| 25 mM | 0.0769 mL | 0.3843 mL | 0.7685 mL | 1.9213 mL | |
| 30 mM | 0.0640 mL | 0.3202 mL | 0.6404 mL | 1.6011 mL | |
| 40 mM | 0.0480 mL | 0.2402 mL | 0.4803 mL | 1.2008 mL | |
| 50 mM | 0.0384 mL | 0.1921 mL | 0.3843 mL | 0.9606 mL | |
| 60 mM | 0.0320 mL | 0.1601 mL | 0.3202 mL | 0.8005 mL |
JZL 184 Related Classifications
HY-15249 Related Classifications
Powered by Bioz